Delving into the Latest Updates on N-butyl-2-cyanoacrylate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Histoacryl

Target-

Mechanism-

Therapeutic Areas

Digestive System DisordersNeoplasmsInfectious Diseases+ [3]

Active Indication-

Inactive Indication

AbscessDental CariesEsophageal and Gastric Varices+ [2]

Originator Organization-

Active Organization-

Inactive Organization

Mansoura University

Tanta University

Drug Highest PhasePendingPhase 3

First Approval Date-

Regulation-

Login to view timeline

Bronchial artery aneurysms are a rare vascular pathology, however bronchial artery pseudoaneurysms are even less commonly observed with minimal cases available in the literature. They are often associated with conditions such as lung infections or malignancies and are typically managed with endovascular embolization. However, complex vascular anatomy may render endovascular approaches unsuitable. Both pathologies require prompt diagnosis and management due to the risk of rupture and subsequent bleeding. This case report aims to describe the diagnosis and successful percutaneous treatment of a bronchial artery pseudoaneurysm of a 59-year-old female patient who presented with hemoptysis on the background of cavitating lung disease secondary to aspergillus colonization. The patient underwent successful percutaneous glue embolization opposed to the typical endovascular approach due to difficult anatomy, leading to complete resolution of the hemoptysis. This case report highlights the importance of US-guided direct percutaneous embolization of a bronchial artery pseudoaneurysm with the use of n-butyl-2-cyanoacrylate as a safe and effective treatment option when endovascular therapy cannot be performed.

01 Jan 2025·Annals of Vascular Surgery

Clinical Application of n-Butyl-2- Cyanoacrylate (NBCA) in the Transarterial Embolization for Type I/II Endoleak During and After EVAR Surgery

Article

Author: Wang, Qi-Bin ; Wang, Xu ; Jiang, Li-Ping ; Ren, Luo-Yi ; Zhang, Hong-Mei

BACKGROUNDExploring the effectiveness and safety of n-butyl-2-cyanoacrylate (NBCA) in the transarterial embolization for common endoleak during and after endovascular repair of aortic aneurysm (EVAR).METHODSA total of 226 patients with abdominal aortic aneurysm (AAA) were treated with EVAR in 4 years from August 2019 to February 2023, including 46 patients with ruptured aneurysms (rAAA). 37 cases, 28 nonruptured AAA patients and 9 rAAA patients, developed endoleak during EVAR surgery and follow-up period and were then treated with NBCA for transarterial embolization. A follow-up was done for at least 6 months to observe its clinical efficacy and adverse reactions.RESULTSAmong 37 cases of endoleak, there were 8 cases of primary type Ia endoleak and one case of primary right type Ib endoleak in the rAAA group, one case of primary type Ib endoleak, 2 cases of secondary type Ia endoleak, and 25 cases of postoperative type II endoleak in the nonruptured AAA group. Three patients with primary type Ia endoleak were treated with coil-assisted NBCA in the rAAA group, while the remaining 34 patients with type I and type II endoleaks were treated with NBCA alone. All transarterial embolization achieved technical success, and the endoleak disappeared. Postoperative hospitalization observation showed that 3 cases of patients in the rAAA group who experienced primary type Ia endoleak during emergency EVAR surgery died within 4 days after surgery due to hemorrhagic shock and multiple organ failure. Two patients experienced non-AAA-related deaths during the follow-up period.CONCLUSIONSTransarterial embolization with NBCA for the treatment of primary and secondary endoleak is a safe and effective method. It can achieve more dense embolization of the aneurysm sac and more complex endoleaks embolization. And, it showed a low recurrence rate of endoleak and the incidence of perioperative complications after surgery, which is worthy of clinical promotion and application. Even in emergency EVAR combined with primary type I endoleak treatment in rAAA patients, patients can still benefit.

01 Dec 2024·Radiology Case Reports

Embolization of a type 2 endoleak using a micropuncture introducer set and a triple-coaxial system through the deep iliac circumflex artery via the ipsilateral femoral artery

Article

Author: Maruchi, Yuki ; Takehara, Yumi ; Saga, Toshinobu ; Shimohira, Masashi ; Ozaki, Shinichi ; Nakano, Yuta ; Ikeda, Shuji ; Suzuki, Kojiro ; Narita, Akiko ; Taniguchi, Marino ; Okada, Hiroaki

An 83-year-old man underwent embolization for a type 2 endoleak following endovascular aortic repair for an abdominal aortic aneurysm. The type 2 endoleak originated from the left iliac circumflex artery, which was located very close to the puncture site in the left femoral artery. This proximity made the embolization procedure challenging; however, by employing a combination of a micropuncture introducer set and a triple-coaxial system, embolization with N-butyl-2-cyanoacrylate was successfully achieved.

100 Deals associated with N-butyl-2-cyanoacrylate

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Esophageal and Gastric Varices	Phase 3	EG	Tanta University	01 Jan 2016
Abscess	Phase 3	EG	Mansoura University	31 Aug 2008
Dental Caries	Phase 3	EG	Mansoura University	31 Aug 2008
Pilonidal Sinus	Phase 3	EG	Mansoura University	31 Aug 2008
Surgical Wound	Phase 3	EG	Mansoura University	31 Aug 2008

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


UEGW	Not Applicable	Esophageal and Gastric Varices	-	N-2-Butyl Cyanoacrylate (Group 1 (G1))	lhqwzxsfnr(xqkzccvfjf) = Minor complications were observed in 38.7% in the G2( N=12) and 29.5%cases in the G1(N=12). Major complications were seen in 9.7% in the G2(N=3), including a case of pulmonary embolism and in 2.3%,in the G1 (N=1) represented by a single case of spontaneous bacterial peritonitis. usctfukjtp (qbrrakwgua ) View more	-	01 Oct 2019
UEGW	Not Applicable	Esophageal and Gastric Varices	-	N-2-Butyl Cyanoacrylate (Group 2 (G2))		-	01 Oct 2019
ARVO2016	Not Applicable	-	-	N-Butyl-2-Cyanoacrylate glue	dadzijbmkz(kzpuszpjvo) = flrdqmjnpf ucxltqixzh (pjuoydmvhf, ± 44.5)	-	01 Sep 2016
ARVO2013	Not Applicable	Blepharoptosis	22	Histoacryl	(ytmfhjeqgk) = uyrcpnvhuo equawdfisx (tccthdtsui )	-	01 Jun 2013
Pubmed \| Am J Gastroenterol	Not Applicable	Bleeding gastric varices	-	N-Butyl-2-Cyanoacrylate (Histoacryl) Glue Injections	qsbxkmzfkz(ivgwhvayng) = xjnitbetck zgjyeazpgm (pjmtlfsypw ) View more	-	01 Dec 2003
Pubmed \| Am J Gastroenterol	Not Applicable	Bleeding gastric varices	-	N-Butyl-2-Cyanoacrylate (Histoacryl) Glue Injections	txwvbqgqhs(dbvfdzgmvi) = zpbdiaiili dudpawidig (xgxmjdibjz ) View more	-	01 Dec 2003
Pubmed \| Gastrointest Endosc	Not Applicable	Bleeding gastric varices	90	N-butyl-2-cyanoacrylate (Histoacryl)	iorxnryvfa(vwurolldou) = zgsojhnmdu vhokldayyi (hexskijhws ) View more	-	01 Aug 2000